Journal
MABS
Volume 8, Issue 7, Pages 1269-1275Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2016.1208330
Keywords
Clearance; cross-interaction; developability; monoclonal antibody; neonatal Fc receptor (FcRn); nonspecificity; polyreactivity; PK; self-interaction
Categories
Funding
- National Institute of General Medical Sciences Interdepartmental Biotechnology Training Program at the National Institutes of Health [T32 GM008334-25]
Ask authors/readers for more resources
The importance of the neonatal Fc receptor (FcRn) in extending the serum half-life of monoclonal antibodies (mAbs) is well demonstrated, and has led to the development of multiple engineering approaches designed to alter Fc interactions with FcRn. Recent reports have additionally highlighted the effect of nonspecific interactions on antibody pharmacokinetics (PK), suggesting an FcRn-independent mechanism for mAb clearance. In this report we examine a case study of 2 anti-interleukin-12/23 antibodies, ustekinumab and briakinumab, which share the same target and Fc, but differ in variable region sequences. Ustekinumab displayed near baseline signal in a wide range of early stage developability assays for undesirable protein/protein interactions, while briakinumab showed significant propensity for self- and cross-interactions. This phenotypic difference correlates with faster clearance rates for briakinumab in both human FcRn transgenic and FcRn knockout mice. These findings support a dominant contribution for FcRn-independent clearance for antibodies with high nonspecificity, and highlight a key role for early stage developability screening to eliminate clones with such high nonspecific disposition PK.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available